141 related articles for article (PubMed ID: 17761967)
1. More support for the judicious use of high-dose interleukin-2 in patients with advanced melanoma.
McDermott DF; Atkins MB
J Clin Oncol; 2007 Sep; 25(25):3791-3. PubMed ID: 17761967
[No Abstract] [Full Text] [Related]
2. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
Ridolfi L; Fiorentini G; Guida M; Michiara M; Freschi A; Aitini E; Ballardini M; Bichisao E; Ridolfi R;
Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
[TBL] [Abstract][Full Text] [Related]
3. [Chemotherapy of malignant melanoma].
Avril MF
Ann Dermatol Venereol; 1988; 115(9):959-68. PubMed ID: 2464963
[No Abstract] [Full Text] [Related]
4. Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma.
Guida M; Riccobon A; Biasco G; Ravaioli A; Casamassima A; Freschi A; Palma MD; Galligioni E; Nortilli R; Chiarion-Sileni V; Picozzo J; Romanini A; Nanni O; Ridolfi R;
Melanoma Res; 2006 Aug; 16(4):317-23. PubMed ID: 16845327
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy, cytokines, and biochemotherapy for melanoma.
Eton O
Cancer Chemother Biol Response Modif; 2005; 22():739-48. PubMed ID: 16110637
[No Abstract] [Full Text] [Related]
6. Administration of high-dose interleukin-2 in a 2-year-old with metastatic melanoma.
Bernhardt MB; Hicks MJ; Pappo AS
Pediatr Blood Cancer; 2009 Dec; 53(7):1346-8. PubMed ID: 19731326
[TBL] [Abstract][Full Text] [Related]
7. [Current chemo- and hormone therapy in disseminated malignant melanoma of the skin].
Akimov MA; Gershanovich ML
Vopr Onkol; 1999; 45(4):341-9. PubMed ID: 10532089
[No Abstract] [Full Text] [Related]
8. Biochemotherapy in patients with advanced head and neck mucosal melanoma.
Bartell HL; Bedikian AY; Papadopoulos NE; Dett TK; Ballo MT; Myers JN; Hwu P; Kim KB
Head Neck; 2008 Dec; 30(12):1592-8. PubMed ID: 18798304
[TBL] [Abstract][Full Text] [Related]
9. Concomitant administration of interleukin-2 during therapeutic vaccinations against cancer: the good, the bad, or the evil?
Andersen MH; Gehl J; Reker S; Geertsen P; Becker JC; thor Stratem P
J Clin Oncol; 2005 Aug; 23(22):5265-7; author reply 5267-8. PubMed ID: 16051975
[No Abstract] [Full Text] [Related]
10. Biochemotherapy for advanced melanoma: maybe it is real.
Khayat D; Bernard-Marty C; Meric JB; Rixe O
J Clin Oncol; 2002 May; 20(10):2411-4. PubMed ID: 12011117
[No Abstract] [Full Text] [Related]
11. Immunotherapy-induced leukoderma from treatment of melanoma with IL-2: a case report and a review of the literature.
Gathings R; Lewallen R; Yosipovitch G
Acta Derm Venereol; 2015 Feb; 95(2):197-200. PubMed ID: 24820241
[TBL] [Abstract][Full Text] [Related]
12. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
[TBL] [Abstract][Full Text] [Related]
13. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P
J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391
[TBL] [Abstract][Full Text] [Related]
14. [Quantitative growth characteristics of pulmonary metastases in cutaneous melanoma].
Mikhnin AE; Barchuk AS; Gershanovich ML; Keller IuM
Vopr Onkol; 2003; 49(6):730-3. PubMed ID: 14976917
[TBL] [Abstract][Full Text] [Related]
15. Management of metastatic melanoma to the breast with high-dose interleukin-2 and surgical resection.
Komenaka IK; DeRaffele G; Hurst-Wicker KS; Kaufman HL
Breast J; 2005; 11(2):158-9. PubMed ID: 15730472
[No Abstract] [Full Text] [Related]
16. Adjuvant therapy of cutaneous melanoma -- current status.
Hansson J
Acta Oncol; 2006; 45(4):369-72. PubMed ID: 16760171
[No Abstract] [Full Text] [Related]
17. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases.
Powell S; Dudek AZ
Anticancer Res; 2009 Oct; 29(10):4189-93. PubMed ID: 19846971
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2-associated bullous drug dermatosis.
Hofmann M; Audring H; Sterry W; Trefzer U
Dermatology; 2005; 210(1):74-5. PubMed ID: 15604553
[No Abstract] [Full Text] [Related]
19. Testicular swelling as the presenting sign of cutaneous malignant melanoma.
Hida T; Saga K; Ogino J; Kagaya M; Kamada A; Kaneko R; Jimbow K; Inoue R; Takahashi A
J Eur Acad Dermatol Venereol; 2006 Mar; 20(3):351-3. PubMed ID: 16503910
[No Abstract] [Full Text] [Related]
20. Induction of tolerance in autoimmune diseases rather than cure of cancer by interleukin-2 therapy.
Dejaco C; Duftner C; Schirmer M
J Clin Oncol; 2006 Jul; 24(20):e34; author reply e35-6. PubMed ID: 16829643
[No Abstract] [Full Text] [Related]
[Next] [New Search]
